Novavax Inc (NVAX)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$7.19
Buy
$7.22
$-0.56 (-7.21%)
Prices updated at 14 Nov 2024, 21:11 EST
| Prices minimum 15 mins delay
Prices in USD
Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2022 | 2023 |
|---|---|---|
| 1,599m | 556m | |
| 696m | 213m | |
| -645m | -567m | |
| -40.32 | -101.82 | |
| -658m | -545m | |
| -605m | -487m | |
| Sales, General and administrative | 489m | 469m |
| Interest expenses | 20m | 14m |
| Provision for income taxes | 4m | 2m |
| Operating expenses | 1,341m | 779m |
| Income before taxes | -654m | -543m |
| Net income available to common shareholders | -658m | -545m |
| -8.42 | -5.41 | |
| Net interest income | -20m | -14m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -8.42 | -5.41 |
| Free cash flow per share | -9.4345 | -8.0985 |
| Book value/share | -6.5782 | -4.8625 |
| Debt equity ratio | - | - |
Balance sheet
Year | 2022 | 2023 |
|---|---|---|
| Current assets | 1,703m | 1,144m |
| Current liabilities | 2,460m | 1,635m |
| Total capital | -468m | -549m |
| Total debt | 550m | 229m |
| Total equity | -634m | -717m |
| Total non current liabilities | - | - |
| Loans | 166m | 168m |
| Total assets | 2,259m | 1,797m |
| Total liabilities | - | - |
| Cash and cash equivalents | 1,337m | 569m |
| Common stock | 86m | 140m |
Cash flow
Year | 2022 | 2023 |
|---|---|---|
| Cash at beginning of period | 1,528m | 1,349m |
| Cash dividends paid | - | - |
| -509m | -773m | |
| Investments (gains) losses | -93m | -59m |
| 1,349m | 584m | |
| Net income | - | - |
| -416m | -714m | |
| -93m | -59m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
